Biodesix, Inc. a leading diagnostics company, is proud to announce that its Chief Financial Officer, Robin Harper Cowie, has been appointed to the Colorado BioScience Association (CBSA) board of directors. As a seasoned executive with extensive experience in the life sciences sector, Ms. Harper Cowie's expertise will play a crucial role in driving the growth and development of Colorado's thriving life sciences community. In joining the CBSA board, Ms. Harper Cowie will collaborate with fellow industry leaders to bolster the supportive ecosystem for life sciences companies throughout the state.

"I am deeply honored to join the CBSA Board of Directors and contribute to the continued growth and advancement of Colorado's life sciences sector," said Robin Harper Cowie. "Biodesix has established a culture of innovation and collaboration, and my appointment to the board presents an opportunity to work alongside other industry leaders in shaping the future of bioscience in our state. I am committed to helping ensure that Colorado remains a vibrant and innovative hub for life sciences companies to thrive and create meaningful impact in people's lives."

Board members collaborate with CBSA staff to facilitate the growth of Colorado's 720+ life sciences companies. CBSA is dedicated to fostering a collaborative life sciences ecosystem and advocating for a supportive business climate, ensuring that life sciences companies can continue to contribute to the advancement of healthcare and medical innovation in Colorado and beyond.

About Biodesix

Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung® nodule risk assessment testing strategy, consisting of the NodifyXL2® and the Nodify CDT® tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung^™ strategy for lung cancer patients integrates the GeneStrat® targeted ddPCR^™ test, the GeneStrat NGS^™ test and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in 2-3 business days, expediting time to treatment. Biodesix also leverages the proprietary and advanced Diagnostic Cortex® AI (Artificial Intelligence) platform, to collaborate with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, visit biodesix.com.

Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, its possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix’s most recent annual report on Form 10-K, filed March 14, 2022 or subsequent quarterly reports on Form 10-Q during 2022, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005191/en/